Vaccine Medical, Development, Scientific, and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.
Global Vaccines Medical Development and Scientific, and Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.
Hum Vaccin Immunother. 2022 Nov 30;18(5):1979846. doi: 10.1080/21645515.2021.1979846. Epub 2022 Apr 28.
This review considers the pathogenesis, diagnosis, and epidemiology of invasive meningococcal disease in infants, to examine and critique meningococcal disease prevention in this population through vaccination. High rates of meningococcal disease and poor outcomes, particularly for very young infants, highlight the importance of meningococcal vaccination in early infancy. Although effective and safe meningococcal vaccines are available for use from 6 weeks of age, they are not recommended globally. Emerging real-world data from the increased incorporation of these vaccines within immunization programs inform recommendations regarding effectiveness, appropriate vaccination schedule, possible long-term safety effects, and persistence of antibody responses. Importantly, to protect infants from IMD, national vaccination recommendations should be consistent with available data regarding vaccine safety, effectiveness, and disease risk.
本综述探讨了婴儿侵袭性脑膜炎奈瑟菌病的发病机制、诊断和流行病学，通过疫苗接种来研究和评估该人群中脑膜炎奈瑟菌病的预防措施。脑膜炎奈瑟菌病的高发病率和不良结局，尤其是对非常年幼的婴儿，突出了在婴儿早期接种脑膜炎球菌疫苗的重要性。尽管有针对 6 周龄以上婴儿使用的有效且安全的脑膜炎球菌疫苗，但它们并非在全球范围内都被推荐使用。在免疫规划中更多地使用这些疫苗所产生的新兴真实世界数据，为疫苗的有效性、适当的接种时间表、可能的长期安全性影响以及抗体反应的持久性提供了信息。重要的是，为了保护婴儿免受侵袭性脑膜炎奈瑟菌病的侵害，国家疫苗接种建议应与关于疫苗安全性、有效性和疾病风险的现有数据保持一致。
